生物医药Ⅱ：DRG/DIP 2.0：回应临床关切优化分组，特例单议利好创新药械

Investment Rating - The industry is rated as "Positive," expecting an overall return exceeding 5% above the CSI 300 Index in the next six months [10]. Core Insights - The introduction of the DRG/DIP 2.0 grouping scheme is expected to address clinical concerns and optimize grouping, which will benefit innovative drugs and medical devices [8]. - The DRG/DIP 2.0 scheme includes 26 major diagnostic categories, 409 core groups, and 634 detailed groups, achieving an enrollment rate of 92.8% and an inter-group difference of 71.0% [5]. - A special case negotiation mechanism has been established to empower medical institutions, allowing them to report cases that do not fit standard payment criteria, which is beneficial for complex and critical cases [6]. - The scheme aims to enhance settlement and clearing levels, reducing financial pressure on medical institutions by organizing monthly settlements and ensuring timely feedback on enrollment and settlement information [7]. Summary by Sections Background of DRG/DIP 2.0 - The DRG/DIP payment reform is being actively promoted by the National Medical Insurance Administration to control costs and standardize medical practices, responding to feedback regarding the precision of existing groupings [4]. Key Optimizations - The DRG 2.0 grouping scheme focuses on optimizing 13 clinical disciplines, including critical care, hematology, oncology, and oral maxillofacial surgery, based on extensive feedback and analysis of case data [5]. Support for Innovation - The DRG/DIP 2.0 scheme is expected to synergize with the "Full Chain Support for Innovative Drug Development Implementation Plan" and various local policies supporting pharmaceutical innovation, benefiting high-quality innovative drug and device manufacturers [8]. - Relevant companies include innovative drug manufacturers such as Heng Rui Medicine, Hansoh Pharmaceutical, and innovative medical device companies like Microelectronic Physiology and Huatai Medical [8].